2024 Hyundai I10 Advance 1.2L Petrol · NG74 AAF

The 2024 Hyundai i10 Advance currently has no recorded MOT history in the official DVSA database. As a vehicle first registered in 2024, it would not normally be required to undergo its first MOT test until three years after registration, meaning the absence of a test record up to the current date of 30 August 2026 is consistent with the statutory testing window rather than a cause for immediate concern. Without any pass, failure, or advisory entries to examine, it is not possible to determine a maintenance trend, classify the vehicle as stable or worsening, or draw any conclusion about its mechanical condition from MOT data alone. Mileage context cannot be established from the supplied record. No odometer readings have been captured at any point, so there is no basis on which to assess whether the i10 has covered high or low annual mileage, identify any gaps in recording, or flag irregular accumulation patterns. A buyer should therefore view the vehicle as unverified in terms of both service interval compliance and mileage progression, and should request a current odometer reading, the V5C logbook, and any supporting service invoices directly from the seller to cross-reference against what is missing from the official record. In the absence of advisory notes or failure items, there are no specific components that the MOT history singles out for attention. For an in-person inspection, a buyer should still carry out a focused assessment of the areas commonly flagged on small city cars of this age and type, including front and rear brake disc and pad condition, suspension strut and spring integrity, underbody and wheel arch corrosion, tyre tread depth and evenness of wear, and exhaust system security. A thorough road test covering steering alignment, clutch bite point, and any warning lights on the dashboard is also advisable, given that the official MOT record provides no reassurance in either direction at this stage. Any pre-purchase inspection by a qualified technician should be treated as essential rather than supplementary. Buying score: 50, risk level: Medium.